← Back to Home

Shifting the Liver Cancer Immune Environment Toward Activity: Preliminary Signals from Preclinical Pelareorep Research

A PNAS study describes how liver cancer develops an immunosuppressive environment; Oncolytics says pelareorep experiments in the study reversed some of these changes. However, these signals do not yet demonstrate patient benefit, and the company says it currently has no intention of developing a liver cancer indication.

By SURL BioNews

For immunotherapy to work, it must do more than release the immune system’s brakes: immune cells also need to enter tumors, recognize cancer cells, and attack them. A hepatocellular carcinoma study traced how these defenses progressively break down and, according to developer Oncolytics Biotech, found that the investigational drug pelareorep shifted some immune markers toward greater activity. However, this remains preclinical evidence, and demonstrating a treatment benefit for liver cancer patients is still some way off.

Published online in the Proceedings of the National Academy of Sciences (PNAS) on September 28, 2026, the study examined how the environment surrounding tumors changes as cirrhosis progresses to hepatocellular carcinoma. The paper’s abstract states that cancer development was accompanied by reduced cytotoxic T-cell infiltration, decreased expression of ICOSL, a ligand involved in T-cell costimulation, and increased signaling that promotes cancer development and immunosuppression. These features were also reproduced in an orthotopic liver tumor mouse model.

The study linked these changes to microRNAs that regulate gene expression: increased activity of miR-21 and miR-155, together with the loss of liver-associated miR-122, jointly affected mechanisms involved in tumor suppression and immune surveillance. This picture suggests that liver cancer development involves not only abnormalities within cancer cells themselves but also a reorganization of the surrounding defense network.

In a September 29 announcement, Oncolytics further stated that pelareorep infection experiments in the study reversed some immunosuppressive features, including increased PD-L1 and ICOSL expression in tumor cells and increased CD8-positive T-cell density. Pelareorep is an investigational viral immunotherapy. The company hopes to use its ability to replicate within tumor cells and mobilize immune responses to create a more favorable environment for other cancer treatments.

These changes provide a rationale for studying combinations with immunotherapy, but they cannot be directly interpreted as efficacy. Increased PD-L1, in particular, is associated with both immune responses and signaling that suppresses T cells; it must be interpreted in the context of the overall environment and actual treatment outcomes. Even if more T cells enter tumors, that observation alone cannot establish that tumors will shrink or that patients will live longer.

The sources of evidence also need to be distinguished: the publicly available PubMed abstract focuses on microRNAs and the liver cancer immune environment and does not describe a pelareorep intervention; drug-related findings currently rely primarily on the company’s account of the paper. The paper’s authors include researchers at The Ohio State University and Oncolytics Chief Medical Officer Thomas C. Heineman. Currently available public information does not provide the complete experimental numerical data needed to assess pelareorep’s effects, nor does it present treatment outcomes in liver cancer patients.

Heineman also said that the company currently has no intention of pursuing a liver cancer indication. The immediate significance of this publication is therefore to add mechanistic clues supporting the concept that pelareorep can alter the tumor immune environment; it does not yet constitute a commitment to clinical development in liver cancer. Whether changes in immune markers can translate into reliable benefits from combination treatment remains a question for subsequent research.

References

  1. GlobeNewswire
  2. Oncolytics Biotech
  3. PubMed / Proceedings of the National Academy of Sciences